2015 Towards an HIV Cure Symposium
18 & 19 July 2015


Opening Session

Keynote Address: Progress and Challenges in HIV Cure Research
Daniel Kuritzkes
Brigham & Women’s Hospital, Harvard Medical School, United States

Community Speaker: Community Involvement in HIV Cure-related Research: Not Just Guinea Pigs
Matthew Sharp
Long-Term Survivor, HIV Education and Advocacy Consultant, United States

Oral Abstract Session 1: Pathways to Establishing and Maintaining HIV Latency

Invited Speaker: HIV-1 broadly neutralizing antibodies: Potential role in HIV treatment approaches

John Mascola
Vaccine Research Center, NIAID/NIH, United States

OA1-1: CTLA-4-expressing memory CD4+ T-cells are critical contributors to SIV viral persistence
Colleen McGary
Emory University, United States

OA1-2: Molecular Determinants of HIV-1 Permissiveness and Persistence in Gut-Homing CD4+ T-Cells Expressing the Th17 Marker CCR6
Delphine Planas
CHUM-Research Center, University of Montreal, Canada

OA1-3: Dasatinib preserves SAMHD1 antiviral activity in CD4+ T cells treated with IL-7
Jose Alcami
Instituto de Salud Carlos III, Spain

OA1-4 LB: Estrogen blocks HIV re-emergence from latency and points to gender-specific differences in HIV reservoirs
Jonathan Karn
Case Western Reserve University School of Medicine, United States

Roundtable: Advancing Paediatric HIV Cure Research

Chair: Jintanat Ananworanich
US Military HIV Research Program, United States

Marie Elizabeth Theunissen
FAMCRU, South Africa

Hugo Soudeyns
CHU Sainte-Justine Research Center and Université de Montréal, Canada

Deborah Persaud
John Hopkins University, United States

Ann Chahroudi
Emory University School of Medicine, United States

Daria Hazuda
Merck, United States

Oral Abstract Session 2: Activating Latent HIV Infection in vitro and in vivo

Invited Speaker: Immune recognition following latency reversal
Marcus Altfeld
Heinrich-Pette Institute, Leibniz Institute for Experimental Virology, Germany

OA2-1: Histone deacetylase inhibitors alter the accumulation of spliced HIV mRNA - implications for virus production
Talia Mota
University of Melbourne, Peter Doherty Institute, Australia

OA2-2: Latency reversal Agent (LRA) Romidepsin Reactivates Latent Virus in Two Rhesus Macaque (RM) Models of Controlled SIV Infection in the Absence of Antiretroviral Therapy (ART)
Benjamin Policicchio
University of Pittsburgh, United States

OA2-3: Vorinostat, Panobinostat, and Romidepsin Nonselectively Activate Transcription from Quiescent HIV-1 Proviruses in HIV-infected Individuals on Long-term Suppressive Anti-retroviral Therapy
Kirston Barton
University of Sydney, Westmead Millennium Institute, Australia

OA2-4: Modulation of HERV family expression after treatment with HDAC inhibitors
Miguel de Mulder Rougvie
George Washington University, United States

OA2-5: Ingenol Efficiently Reactivates Latent HIV in cells from aviremic patients
Vicente Planelles
University of Utah, United States

OA2-6 LB: CD4 Mimetics Sensitize HIV-1-Infected Cells to ADCC
Andres Finzi
The CHUM Research Center, University of Montreal & McGill University, Canada

Roundtable: Combination Therapy Trials

Chair: Daniel Kuritzkes
Brigham & Women’s Hospital, Harvard Medical School, United States

Brigitte Autran
Hôpital Pitié Salpêtrière, CIMI-Paris, UPMC/INSERM U1135, France

Joseph Eron
University of North Carolina, United States

Irina Tcherepanova
Argos Therapeutics, Inc., United States

Jeffrey Lifson
Frederick National Laboratory for Cancer Research, United States

David Evans
Project Inform, United States


With the support of: